Clinical Trial Update: Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial investigating rituximab therapy to prevent cardiac allograft vasculopathy in heart transplant recipients; the study was terminated with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Allograft Vasculopathy
• Heart Transplant Recipients

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cardiac Allograft Vasculopathy, Heart Transplant Recipients | Phase 2 | Status: TERMINATED | Results posted: 2017-04-11